(Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)

Covid-19 roundup: Pfiz­er, BioN­Tech forge ahead with en­hanced vac­cine; Brii moves on an­ti­body to counter sub­vari­ants

While Pfiz­er and BioN­Tech’s Covid-19 vac­cine has been one of the pri­ma­ry treat­ments so far in the pan­dem­ic, both com­pa­nies are still ad­just­ing and mak­ing im­prove­ments amidst the spread of the Omi­cron vari­ant and its sub­vari­ants.

And now the lat­est step has come through. Both com­pa­nies an­nounced Wednes­day that they have kicked off a Phase II study to eval­u­ate an en­hanced ver­sion of the vac­cine can­di­date at a 30 µg dose lev­el.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.